Hence, this study concluded that p16 immunohistochemistry is a cost effective and convenient method for evaluating CDKN2A homozygous deletions in gliomas, as an alternative to expensive genomic sequencing [44]. This evidence concerns the gene CDKN2A and central nervous system cancer.